文献速递自身免疫性与大疱性皮肤病

大疱性类天疱疮:甲泼尼龙联合硫唑嘌呤与氨苯砜的随机对照研究

An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone.
PubMed 文献 · Br J Dermatol · 2017-10-29

因入组患者仅54例低于预期,主要和次要终点结果无显著或仅勉强显著差异;氨苯砜的激素节约潜力略高于硫唑嘌呤,两种联合方案1年死亡率均较低。

要点

  • 氨苯砜联合甲泼尼龙的激素节约潜力略高于硫唑嘌呤联合方案。
  • 两组不良事件数无显著差异,1年死亡率均为8%(4例)。
  • 因样本量低于预期,主要和次要终点未达或仅勉强达统计学显著。

核心结论

  • 氨苯砜的激素节约潜力略高于硫唑嘌呤,但主要和次要终点因样本量不足未达或仅勉强达显著差异。
  • 两种联合方案不良事件数无显著差异,1年死亡率相对较低。

研究设计与样本

  • 前瞻性、多中心、随机、非盲临床试验,纳入54例大疱性类天疱疮患者。
  • 患者来自德国和奥地利的9个皮肤科,依据临床皮损、直接免疫荧光阳性及血清自身抗体检测确诊。

主要发现

  • 8例患者(硫唑嘌呤组5例,氨苯砜组3例)停用甲泼尼龙,中位停药时间硫唑嘌呤组251天,氨苯砜组81天。
  • 两组不良事件数无显著差异,观察期12个月内4例(8%)死亡。

关键数值与推荐

  • 主要终点为甲泼尼龙完全减停时间,最重要次要终点为累积激素剂量。

临床怎么用

  • 对于大疱性类天疱疮,口服甲泼尼龙联合氨苯砜或硫唑嘌呤均可作为激素节约方案。
  • 氨苯砜可能在更短时间內减少激素累积剂量,但需结合患者个体情况选择。

局限性

  • 实际入组患者数(54例)低于预期,导致主要和次要终点结果无显著或仅勉强显著差异。
  • 研究为非盲设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current treatment of bullous pemphigoid (BP) is based on the long-term use of topical and/or systemic corticosteroids, which are associated with a high rate of adverse events and increased mortality. OBJECTIVES: To study the corticosteroid-sparing potential of azathioprine and dapsone. METHODS: This was a prospective, multicentre, randomized, nonblinded clinical trial that compared the efficacy and safety of two parallel groups of patients with BP treated with oral methylprednisolone 0·5 mg kg-1 per day in combination with either azathioprine 1·5-2·5 mg kg-1 per day or dapsone 1·5 mg kg-1 per day. Nine German and Austrian departments of dermatology included 54 patients based on clinical lesions, positive direct immunofluorescence (IF) microscopy and detection of serum autoantibodies by indirect IF microscopy, immunoblotting or enzyme-linked immunosorbent assay. The primary end point was the time until complete tapering of methylprednisolone, and the most important secondary end point was the cumulative corticosteroid dose. RESULTS: In eight patients (five azathioprine, three dapsone), methylprednisolone could be discontinued after a median time of 251 days in the azathioprine group and 81 days in the dapsone group. The median cumulative corticosteroid dose was 2·65 g for azathioprine compared with 1·92 g for dapsone (P = 0·06). The median numbers of days when corticosteroids were applied were 148 and 51, respectively (P = 0·24). No significant difference in the number of adverse events was seen between the treatment arms. Four patients (8%) died within the observation period of 12 months. CONCLUSIONS: Due to the lower than intended number of patients, the results of the primary and secondary end points were not or only barely significant. Dapsone appeared to have a moderately higher corticosteroid-sparing potential than azathioprine. The combination regimen of either drug with oral methylprednisolone is associated with a relatively low 1-year mortality in this vulnerable patient population.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Sticherling M, Franke A, Aberer E, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017. PMID: 28494097. doi:10.1111/bjd.15649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。